Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

5.1K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Human Genetics01:28

Human Genetics

750
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis.

Blood advances·2026
Same author

G6PD activity in pediatric patients with the G6PD Ilesha variant: A case series G6PD Ilesha variant in Pediatric patients.

Clinical biochemistry·2026
Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT<sub>3</sub> Receptor Antagonists: 2026 Update.

Clinical pharmacology and therapeutics·2026
Same author

Precision-Based Care: A Multidisciplinary Approach.

Journal of pediatric hematology/oncology nursing·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.

Clinical pharmacology and therapeutics·2026
Same journal

Common Principles Underlie Mitochondrial DNA Heteroplasmy Dynamics in the Germline and Soma.

Annual review of genomics and human genetics·2026
Same journal

Human Sex Chromosome Biology in the Genomic Era.

Annual review of genomics and human genetics·2026
Same journal

Beyond TADs and Compartments: Mesoscale Chromatin Folding and Its Dynamics in Transcriptional Regulation.

Annual review of genomics and human genetics·2026
Same journal

Experimental and Computational Approaches to Identify Noncoding Pathogenic Variation in Rare Disease.

Annual review of genomics and human genetics·2026
Same journal

How Studying Rare Disease Leads to Mechanistic Insights and Therapeutic Development: Lessons from Nonmammalian Models.

Annual review of genomics and human genetics·2026
Same journal

Synthetic Regulatory Genomics.

Annual review of genomics and human genetics·2026
See all related articles

Related Experiment Video

Updated: Sep 24, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K

Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

Cyrine E Haidar1, Kristine R Crews1, James M Hoffman1,2

  • 1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: cyrine.haidar@stjude.org, kristine.crews@stjude.org, james.hoffman@stjude.org, mary.relling@stjude.org, kelly.caudle@stjude.org.

Annual Review of Genomics and Human Genetics
|May 10, 2022
PubMed
Summary
This summary is machine-generated.

Preemptive pharmacogenomic testing improves medication safety by providing genetic insights at prescription. Implementing this approach requires addressing logistical challenges for widespread clinical adoption.

Keywords:
clinical decision supportgenomic medicineindividualized medicinepersonalized medicinepharmacogeneticspharmacogenomicsprecision medicine

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.1K
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.2K

Related Experiment Videos

Last Updated: Sep 24, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.1K
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.2K

Area of Science:

  • Clinical Pharmacology
  • Genetics
  • Personalized Medicine

Background:

  • Pharmacogenomic testing enhances medication safety and efficacy.
  • Most individuals (90-95%) possess actionable genotypes for pharmacogenes.
  • Preemptive testing integrates genetic information at the time of prescribing.

Purpose of the Study:

  • To review the rationale for preemptive pharmacogenomic testing.
  • To outline best practices for implementing preemptive pharmacogenomics.
  • To address logistical concerns hindering widespread adoption.

Main Methods:

  • Literature review of existing pharmacogenomic implementation studies.
  • Analysis of best practices from institutions with established programs.
  • Identification of key logistical challenges and potential solutions.

Main Results:

  • Preemptive pharmacogenomic testing offers significant potential for improving patient care.
  • Key logistical hurdles include reimbursement, long-term result reporting, and data portability.
  • Successful implementation relies on institutional support and standardized protocols.

Conclusions:

  • Preemptive pharmacogenomic testing is crucial for maximizing medication safety and efficacy.
  • Addressing logistical barriers is essential for successful and sustainable implementation.
  • Learning from existing institutional experiences can guide future adoption strategies.